We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Seracare Life Sciences (MM) | NASDAQ:SRLS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.01 | 0 | 01:00:00 |
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person
*
McLain Brian |
2. Issuer Name
and
Ticker or Trading Symbol
SERACARE LIFE SCIENCES INC [ SRLS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) VP, Finance and Controller |
C/O SERACARE LIFE SCIENCES, INC., 37 BIRCH STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
MILFORD, MA 01757 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 4/20/2012 | D | 34554 | D | (1) | 0 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (Right to Buy) | $1.25 | 4/20/2012 | D | 12000 | (3) | 11/21/2013 | Common Stock | 12000 | (4) | 0 | D | ||||
Stock Option (Right to Buy) | $3.00 | 4/20/2012 | D | 8000 | (3) | 11/18/2014 | Common Stock | 8000 | (4) | 0 | D | ||||
Stock Option (Right to Buy) | $3.00 | 4/20/2012 | D | 4000 | (2) | 11/18/2014 | Common Stock | 4000 | (4) | 0 | D |
Explanation of Responses: | |
( 1) | Pursuant to the Agreement and Plan of Merger dated as of February 12, 2012, as amended by Amendment No. 1 to Agreement and Plan of Merger dated as of February 27, 2012, among SeraCare Life Sciences, Inc., Project Plasma Holdings Corporation and Project Plasma Merger Corp. (the "Merger Agreement"), each share of SeraCare Life Sciences, Inc.'s common stock was exchanged for $4.00 in cash, without interest and less any applicable withholding taxes. |
( 2) | Pursuant to its terms, the stock option accelerated and became fully vested as of the closing of the merger. |
( 3) | This stock option is fully vested. |
( 4) | Pursuant to the Merger Agreement, each stock option was cancelled in the merger in exchange for the right to receive an amount in cash, without interest, equal to the product of the number of shares issuable upon the exercise of such stock option and $4.00 minus the exercise price of such stock option, less any applicable withholding taxes. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
McLain Brian
C/O SERACARE LIFE SCIENCES, INC. 37 BIRCH STREET MILFORD, MA 01757 |
|
|
VP, Finance and Controller |
|
Signatures
|
||
/s/ Gregory A. Gould, Attorney-in-fact | 4/20/2012 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Seracare Life Sciences Chart |
1 Month Seracare Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions